Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulax Dose-Finding Study for Benign Masseteric Hypertrophy
NCT04443244Phase 2Completed
- Sponsor
- Hugel
- Start
- May 2020
- Primary completion
- Nov 2020
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of letibotulinumtoxinA in benign masseteric hypertrophy (BMH), sponsored by Hugel. Started May 2020; status: completed.
02
Drugs
letibotulinumtoxinA
03
Conditions
benign masseteric hypertrophy (BMH)
Beyond the preview
Go deeper on NCT04443244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443244.